Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | PNMT | P11086 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | TDP2 | O95551 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29650705 | 0.79 | PRKCI (0.52) | ADRA2APNMTADRA2BADRA2CPRKCI | |
| SCHEMBL1007568 | 0.79 | PRKCI (0.52) | ADRA2APNMTADRA2BADRA2CPRKCI | |
| SCHEMBL17287441 | 0.79 | ADRA2A (0.34) | ADRA2APNMTADRA2BADRA2CTDP2 | |
| SCHEMBL2177890 | 0.76 | LMNA (0.41) | PNMTPRKCIDYRK1APKM | |
| SCHEMBL1122456 | 0.76 | MAPT (0.40) | PRKCIDYRK1APKM | |
| SCHEMBL30273127 | 0.76 | MAPT (0.40) | PRKCIDYRK1APKM | |
| SCHEMBL2452325 | 0.76 | PRKCI (0.33) | PRKCIDYRK1APKM | |
| SCHEMBL10770264 | 0.76 | ESR2 (0.45) | PRKCI | |
| Hydrochloric Acid SCHEMBL4269942 | 0.74 | MAPT (0.43) | PRKCIDYRK1A | |
| SCHEMBL753333 | 0.72 | DYRK1A (0.46) | ADRA2APNMTADRA2BADRA2CPRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3911645-B1 | 5-MEMBERED HETEROARYL COMPOUNDS CONTAINING A HYDROXAMATE MOIETY AND THEIR USE | UNIV LILLE (FR) | 2022-12-07 | — | — | EP | disclosed |
| US-20220073475-A1 | 5-MEMBERED HETEROARYL COMPOUNDS CONTAINING A HYDROXAMATE MOIETY AND THEIR USE | UNIVERSITÉ PARIS CITÉ (FR) | 2022-03-10 | — | — | US | disclosed |
| EP-3911645-A1 | 5-MEMBERED HETEROARYL COMPOUNDS CONTAINING A HYDROXAMATE MOIETY AND THEIR USE | Université de Lille (FR) | 2021-11-24 | — | — | EP | disclosed |
| WO-2020148403-A1 | 5-MEMBERED HETEROARYL COMPOUNDS CONTAINING A HYDROXAMATE MOIETY AND THEIR USE | UNIVERSITE DE LILLE (FR) | 2020-07-23 | — | — | WO | disclosed |
| US-9579320-B2 | Inhibitors of syk and JAK protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150297595-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. | 2015-10-22 | — | — | US | disclosed |
| EP-2323993-B1 | 2,6-DIAMINO- PYRIMIDIN- 5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS | PORTOLA PHARM INC (US) | 2015-06-03 | — | — | EP | disclosed |
| US-8952027-B2 | Inhibitors of syk and JAK protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20130165431-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8349860-B2 | Inhibitors of syk and JAK protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8318755-B2 | Inhibitors of SYK and JAK protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120130073-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120101275-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-8063058-B2 | Inhibitors of syk and JAK protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2323993-A2 | 2,6-DIAMINO- PYRIMIDIN- 5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS | Portola Pharmaceuticals, Inc. (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100048567-A1 | Inhibitors of syk and JAK protein kinases | PORTOLA PHARMACEUTICALS INC. (US) | 2010-02-25 | — | — | US | disclosed |
| WO-2009136995-A2 | INHIBITORS OF SYK PROTEIN KINASE | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20080176862-A1 | Cognitive impairment, Alzheimer disease, neurodegeneration, dementia; such as 3'-(2-amino-4-(2-chloropyridin-4-yl)-1-methyl-5-oxo-4,5-dihydro-1H-imidazol-4-yl)-5-chlorobiphenyl-3-yl methanesulfonate; Beta site APP Cleaving Enzyme (BACE) inhibitors | ASTRAZENECA AB (SE) | 2008-07-24 | — | — | US | disclosed |
| WO-2008076046-A1 | NOVEL 2-AMINO-5, 5-DIARYL-IMIDAZOL-4-ONES | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297595-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | SYK, BTK, JAK1 | ADRA2A 4814/4885PNMT 1699/4885ADRA2B 4544/4885 |
| US-20080176862-A1 | Cognitive impairment, Alzheimer disease, neurodegeneration, dementia; such as 3'-(2-amino-4-(2-chloropyridin-4-yl)-1-methyl-5-oxo-4,5-dihydro-1H-imidazol-4-yl)-5-chlorobiphenyl-3-yl methanesulfonate; Beta site APP Cleaving Enzyme (BACE) inhibitors | BACE1, BACE2, PSEN1 | ADRA2A 3825/4885PNMT 469/4885ADRA2B 1963/4885 |
| US-20130165431-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | SYK, BTK, JAK1 | ADRA2A 4814/4885PNMT 1699/4885ADRA2B 4544/4885 |
| US-20220073475-A1 | 5-MEMBERED HETEROARYL COMPOUNDS CONTAINING A HYDROXAMATE MOIETY AND THEIR USE | HDAC5, HDAC6, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ADRA2A 4533/4885PNMT 3012/4885ADRA2B 4264/4885 |
| US-20120130073-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | SYK, BTK, JAK1 | ADRA2A 4814/4885PNMT 1699/4885ADRA2B 4544/4885 |
| US-20120101275-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | SYK, BTK, JAK1 | ADRA2A 4814/4885PNMT 1699/4885ADRA2B 4544/4885 |
| US-20100048567-A1 | Inhibitors of syk and JAK protein kinases | SYK, BTK, JAK1 | ADRA2A 4814/4885PNMT 1699/4885ADRA2B 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.